MLH1 and ovarian carcinoma: In cisplatin-resistant sublines independently derived from the ovarian cancer cell line A2780, increased methylation of the MLH1 promoter, resulting in loss of MLH1 expression, was observed, and the authors concluded that hypermethylation-dependent inactivation of MMR emerged in a cisplatin-resistant phenotype [60].